Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8844648 | 0.80 | — | — | |
| SCHEMBL27560608 | 0.78 | EPHX1 (0.36) | ALDH1A1NPSR1LMNAEPHX1 | |
| SCHEMBL27856400 | 0.75 | CYP1A2 (0.38) | ALDH1A1NPSR1LMNAEPHX1CASP1 | |
| SCHEMBL28992198 | 0.73 | LMNA (0.56) | ALDH1A1GAANPSR1LMNACASP1 | |
| SCHEMBL27650918 | 0.72 | ALDH1A1 (0.48) | ALDH1A1GAANPSR1EPHX1CASP1 | |
| SCHEMBL17470137 | 0.68 | CYP2C19 (0.49) | ALDH1A1GAANPSR1LMNAEPHX1 | |
| SCHEMBL1593817 | 0.68 | CYP2C19 (0.49) | ALDH1A1GAANPSR1LMNAEPHX1 | |
| Chloroacetic Acid SCHEMBL1783141 | 0.67 | TSHR (0.48) | ALDH1A1LMNAEPHX1 | |
| Acrylic Acid SCHEMBL28944965 | 0.67 | LMNA (0.48) | ALDH1A1GAALMNAEPHX1HTT | |
| Acrylic Acid SCHEMBL8441153 | 0.67 | LMNA (0.48) | ALDH1A1GAALMNAEPHX1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102153553-A | Oral administration carbapenem compound containing amino sulfonamide-azetidine | SHANDONG XUANZHU PHARMACEUTICAL CO LTD OWN | 2011-08-17 | — | — | CN | disclosed |